雲頂新耀(01952.HK)獲新加坡科技研究局授出新冠病毒藥技術
雲頂新耀-B(01952.HK)公布,新加坡科技研究局旗下A*ccelerate向公司附屬Everest SG授出一項於授權技術項下的獨家、不可轉讓、可轉授權、附特許使用權費及可因故撤回的授權許可,以在全球範圍內利用授權產品用於治療冠狀病毒及其他疾病,並對授權技術進行改進。
授權許可協議項下的費用包括250萬美元授權使用費,最多為1.07億美元潛在開發里程碑付款,及介乎1,500萬美元及1.05億美元的潛在銷售里程碑付款。
授權技術中的先導化合物是EDDC-2214,是一種針對2019冠狀病毒病的新型、強力3CL蛋白(酉每)抑制劑,公司將其開發作為2019冠狀病毒病口服抗病毒藥物。公司指,評估EDDC-2214的臨床試驗有望於今年啟動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.